Two Phase III clinical research results on hypoglycemic and weight reducing drugs jointly completed by multiple research and development units in China were published online in the top international scientific journal Nature early this morning Beijing time. It is reported that this is the first time that the results of China's Phase III research on new drugs have been published in Nature, and it is also the first time since the journal was founded that two Phase III clinical research results have been simultaneously published back-to-back in the fields of metabolism and endocrine diseases. The impact factor of Nature magazine has long been among the top comprehensive scientific journals in the world, and is recognized as a research and development indicator in the global scientific community. The two Phase III clinical research achievements published this time are the research on the single drug treatment of marsidotide in patients with type 2 diabetes (DREAMS-1) and the research on the combined use of marsidotide with oral hypoglycemic drugs (DREAMS-2). The former was jointly completed by the team of Professor Zhu Dalong from Gulou Hospital affiliated to Nanjing University School of Medicine, the team of Zhao Jiajun from provincial hospital affiliated to Shandong First Medical University and the team of Dr. Cinda Biomoney Radium, and the latter was jointly completed by the team of Professor Guo Lixin from Beijing Hospital, Professor Zhang Bo and Professor Yang Wenying from China-Japan Friendship Hospital and other research center teams nationwide and the team of Cinda Biologic R&D. Masidu Peptide is the world's first and only approved GCG/GLP-1 natural dual target weight loss and glucose lowering drug independently developed by Xinda Biotechnology. GLP-1 is the English abbreviation for glucagon like peptide-1, which is secreted after meals and can promote insulin secretion, reduce postprandial blood sugar, slow down gastrointestinal motility, and cause satiety. ”According to Dr. Qian Lei, GLP-1 drugs can activate GLP-1 receptors, increase insulin secretion, and achieve therapeutic effects of lowering blood sugar and weight loss. GCG is the abbreviation for glucagon, secreted by pancreatic alpha cells in the pancreas, and its receptor is mainly expressed in the liver. Activating GCG receptors can enhance fat oxidation, promote energy expenditure, and improve liver fat metabolism. The combination of GCG and GLP-1 targets can comprehensively solve complex metabolic problems such as visceral fat accumulation and insulin resistance in obese patients through a dual mechanism of 'appetite suppression+accelerated metabolism'. ”At present, Marsdopeptide has been approved for two indications of diabetes and weight loss in China, and seven phase III studies have been carried out, covering diabetes, obesity and related complications. The phase Ib clinical study in obese adolescents has reached the main end point, and the results show that the drug can bring weight loss and multiple metabolic benefits to adolescents. In May of this year, the results of the Phase III weight loss study (GLORY-1) of Masidogrel were published in the top international medical research journal, the New England Journal of Medicine (NEJM). The results of two clinical studies published today in Nature indicate that mesidogrel is superior to placebo or dulaglutide (1.5mg) in blood glucose control and weight loss, and both show improvement in multiple cardiovascular metabolism, liver, and kidney related indicators. Professor Guo Lixin, a well-known endocrinologist and Beijing Hospital expert in China, stated that the Phase III study of Masidogrel not only improves blood sugar and weight, but also has good safety. The publication of relevant research results in the journal Nature reflects the high recognition of the quality and scientific value of original clinical research in China by the international academic community, and is expected to provide richer and more cutting-edge options for global clinical treatment